Phase II study to evaluate the tolerability, safety and efficacy of sublingual immunotherapy in patients with allergy to grass pollen.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ROXALL MEDICINA ESPAÑA, SA
- Phase: II
- Execution start: 07/09/2020
- End of execution: 30/11/2021
- IP: JOSE FERNANDO FLORIDO LOPEZ